Clinical Trials Directory

Trials / Unknown

UnknownNCT04582305

Bleomycin Jet Injections in Keloids

Intralesional Bleomycin Treatment of Keloids Using an Electronic Pneumatic Jet Injector: a Double-blind Randomized, Placebo-controlled Trial With Split-lesion Design

Status
Unknown
Phase
Phase 4
Study type
Interventional
Enrollment
14 (actual)
Sponsor
Erasmus Medical Center · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This is a single center, double-blind (patient and investigator), randomized, placebo-controlled study with a split-lesion design, in which selected keloids will receive three consecutive treatments of a) bleomycin and b) placebo (saline (NaCl 0,9%)), administered with an electronic pneumatic jet injector.

Detailed description

This is a single center, double-blind (patient and investigator), randomized, placebo-controlled study with a split-lesion design.All study procedures will be performed at the Department of Dermatology, Erasmus MC Medical Center in patients referred for scar treatment to our outpatient clinic. Clinical photos will be obtained after signing the informed consent form by patient and investigator. Study visits and clinical assessments will be scheduled at baseline, 4 weeks, 8 weeks, and 12 weeks. Measurements include clinical photography, scar volume measured by 3D-camera, POSAS questionnaire, laser speckle contrast imaging to visualize keloid scar vascularization, measurement of residue formation on the skin, and a treatment related questionnaire. The keloid will be divided into two treatment areas, and randomly assigned to three consecutive treatments of: a) bleomycin and b) placebo (saline (NaCl 0,9%)), administered with an electronic pneumatic jet injector.

Conditions

Interventions

TypeNameDescription
DRUGBleomycinIntralesional bleomycin treatment administered with an electronic pneumatic jet injector
DRUGNormal salineIntralesional placebo treatment of normal saline administered with an electronic pneumatic jet injector

Timeline

Start date
2022-03-18
Primary completion
2022-11-18
Completion
2023-03-30
First posted
2020-10-09
Last updated
2022-11-09

Locations

1 site across 1 country: Netherlands

Source: ClinicalTrials.gov record NCT04582305. Inclusion in this directory is not an endorsement.